Article:Why are Functional Amyloids Non-Toxic in Humans? (5745454)

From ScienceSource
Jump to: navigation, search

This page is the ScienceSource HTML version of the scholarly article described at https://www.wikidata.org/wiki/Q46302841. Its title is Why are Functional Amyloids Non-Toxic in Humans? and the publication date was 2017-09-22. The initial author is Matthew P. Jackson.

Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.



Converted JATS paper:

Journal Information

Title: Biomolecules

Why Are Functional Amyloids Non-Toxic in Humans?

  • Matthew P. Jackson
  • Eric W. Hewitt
  • Margaret Sunde (Academic Editor)
  • Matthew Chapman (Academic Editor)
  • Daniel Otzen (Academic Editor)
  • Sarah Perrett (Academic Editor)

School of Molecular and Cellular Biology and Astbury Centre for Structural Molecular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK; m.p.jackson@leeds.ac.uk

Publication date (epub): 9/2017

Publication date (collection): 12/2017

Abstract

Amyloids were first identified in association with amyloidoses, human diseases in which proteins and peptides misfold into amyloid fibrils. Subsequent studies have identified an array of functional amyloid fibrils that perform physiological roles in humans. Given the potential for the production of toxic species in amyloid assembly reactions, it is remarkable that cells can produce these functional amyloids without suffering any obvious ill effect. Although the precise mechanisms are unclear, there are a number of ways in which amyloid toxicity may be prevented. These include regulating the level of the amyloidogenic peptides and proteins, minimising the production of prefibrillar oligomers in amyloid assembly reactions, sequestrating amyloids within membrane bound organelles, controlling amyloid assembly by other molecules, and disassembling the fibrils under physiological conditions. Crucially, a better understanding of how toxicity is avoided in the production of functional amyloids may provide insights into the prevention of amyloid toxicity in amyloidoses.

Paper

1. Introduction

Amyloid fibrils are cross-β assemblies and were first identified in amyloidoses, an array of devastating human diseases [[1],[2],[3]]. To date, over 30 different sequences are now known to misfold to form amyloids in amyloidoses, including amyloid-β (Aβ) in Alzheimer’s disease, α-synuclein in Parkinson’s disease, huntingtin in Huntington’s disease, and β2-microglobulin (β2m) in dialysis-related amyloidosis (DRA) [[4],[5],[6],[7]]. Crucially, amyloid formation can result in degeneration of the affected tissue [[5],[8]]. This intimate association with human disease led to amyloid fibril assembly being considered as a pathological process. It was therefore surprising to discover that amyloid fibrils perform physiological functions in organisms ranging from prokaryotes to humans [[9],[10]]. In humans, functional amyloids have been proposed to participate in an array of physiological processes including pigmentation, the storage of peptide hormones, the fertilisation of oocytes by sperm, antimicrobial responses, regulated necrosis, and cellular responses to stress [[11],[12],[13],[14],[15],[16],[17],[18],[19],[20],[21]]. Nonetheless, the toxicity of amyloid formation in amyloidoses raises an important question that this review article will address, namely, how under normal circumstances can human cells produce functional amyloid fibrils without suffering any obvious deleterious effects?

2. Amyloid Fibril Assembly and Structure

The assembly of amyloid fibrils from their peptide and protein precursors is a nucleation dependent process [[6],[7]]. There is an initial lag phase, which ends in the formation of a fibril nucleus (Figure 1) [[6],[7]]. This initiates the exponential phase in which fibrils assemble, before fibril growth then plateaus in the equilibrium phase [[6],[7]]. The resultant amyloid fibrils are unbranched fibres of 5–15 nm in width, composed of two or more protofilaments and can be many microns in length [[6],[7]]. Within the protofilaments, the individual subunits form a cross-β structure, corresponding to ribbon-like arrays of β-sheets that are aligned perpendicular to the long axis of the fibril (Figure 1) [[6],[7],[22]]. The cross-β structure of amyloid fibrils produces a distinctive X-ray fiber diffraction pattern, with reflections at 4.7 Å and ~10 Å, corresponding to the hydrogen bonding distances between β-strands and side chain packing between the sheets, respectively [[3]]. Amyloid fibrils also have characteristic tinctorial properties, binding to the dyes thioflavin-S, thioflavin-T, and Congo red, the latter exhibiting green birefringence in polarised light when bound to amyloids [[3]]. In addition, antibodies that recognise conformational epitopes in amyloid fibrils and their assembly intermediates have been generated [[23],[24],[25]].

Although the core of all amyloid fibrils is a cross-β structure, and hence the fibrils share some common properties, the precise arrangement of the subunits in the protofilaments is dependent on the precursor [[6],[7],[22]]. Moreover, amyloid fibrils exhibit heterogeneity, with the same precursor being able to produce self-propagating fibril polymorphs with distinctive molecular structures, morphologies, and biological properties [[26],[27]].

3. The Amyloidoses and Mechanisms of Amyloid Toxicity

Amyloid fibrils generated in amyloidoses represent abnormal aggregates that result from the misfolding of the precursor peptide or protein [[6],[7]]. These amyloid fibrils can deposit into extracellular plaques, as observed in Alzheimer’s disease and dialysis-related amyloidosis, whereas in Parkinson’s and Huntington’s amyloids are present in intracellular inclusions [[5]]. Identifying the species produced in amyloid assembly reactions that are the culprits of toxicity in amyloidoses and elucidating their mechanisms of action is a priority. A plethora of experimental studies have shown that prefibrillar oligomers produced in the lag phase of amyloid assembly reactions are toxic both in vitro and in vivo [[28],[29]]. Crucially, toxic prefibrillar oligomers are not unique to the peptides and proteins that form amyloids in human disease; they can also be generated from sequences that do not form amyloids naturally [[30],[31],[32]]. The implication is that amyloid assembly reactions have the inherent potential to produce toxic species irrespective of the amyloidogenic precursor. Analyses of the mechanisms of toxicity have revealed that cellular membranes are a major target for prefibrillar oligomers, with membrane permeabilisation resulting in elevated intracellular Ca2+, the induction of oxidative stress and cell death [[31],[33],[34]].

Whilst prefibrillar oligomers are important participants in amyloid disease, they can be transient and heterogenous in nature [[28],[29]]. For example, there are multiple different oligomeric forms of Aβ: dimers, trimers, tetramers, pentamers, decamers, Aβ-derived diffusible ligands, dodecamers, and Aβ*56 [[35],[36],[37],[38],[39],[40]]. Moreover, oligomers can exhibit markedly different biological properties, with the same peptide or protein producing both toxic and non-toxic oligomers [[41],[42]]. Adding to this complexity, prefibrillar oligomers are unlikely to be the only toxic species associated with amyloids. Fibrils exhibit a range of disease-relevant properties, including the capacity to damage membranes either via direction interaction or by elongating on the membrane surface [[43],[44],[45],[46]]. Fibrils can also act as an additional source of oligomers by either shedding from their ends or by providing a surface that catalyses new oligomer formation [[45],[47],[48],[49]]. Thus, when examining the mechanisms of amyloid toxicity, an array of prefibrillar oligomers, fibrils, and fibril-derived oligomers need to be considered.

4. Functional Amyloids and Their Physiological Roles in Humans

Amyloids can also be produced as a natural protein fold with the fibrils performing an array of physiological functions. The fibrous structure of amyloid fibrils facilitates their use as scaffolds for biochemical processes, whereas the compact nature of the amyloid fold is ideal for the storage of proteins and peptides. In humans, several different peptides and proteins have been shown to self-assemble into fibrils that perform physiological functions and that have properties consistent with amyloids [[11],[12],[13],[14],[15],[16],[17],[18],[19],[20],[21]]. The experimental evidence for the formation of amyloid fibrils by these peptides and proteins is summarised in Table 1. For clarity, in this article, the term amyloid is used when a cross-β X-ray fiber diffraction pattern and amyloid-specific dye binding have both been demonstrated. Fibrils that bind amyloid-specific dyes, but that have not been shown experimentally to have a cross-β structure, will be referred to as amyloid-like.

Amyloid fibrils of pigment cell-specific pre-melanosomal protein (PMEL) are localised to the lumen of melanosomes, a specialised organelle present in the skin and eyes that acts as the site for the synthesis of the pigment melanin [[17],[50],[51]]. The fibrils are thought to be scaffolds for the deposition of the tyrosine-based polymer melanin, sequestering toxic intermediates in melanin synthesis [[17],[50],[51]]. An analogous scaffold function has been proposed for receptor-interacting protein 1 (RIP1)/RIP3 amyloid fibrils [[20]]. In regulated necrosis, RIP1 and RIP3 kinases co-assemble into heterodimeric amyloid fibrils that act as a signalling complex known as the necrosome [[52]]. The necrosome recruits free RIP3, resulting in its autophosphorylation and the subsequent recruitment and phosphorylation of mixed-lineage kinase domain-like (MLKL), a key downstream substrate in regulated necrosis [[52]].

In cells subjected to stressors amyloid-bodies (A-bodies) act as stores for proteins [[11]]. Both acidosis and heat shock induce the expression of ribosomal intergenic noncoding RNA (rIGSRNA), which seeds A-body formation in the nucleus [[11]]. Multiple proteins (>180) assemble into the A-bodies, including proteins involved in cell cycle progression and DNA synthesis, resulting in cells entering a dormant state [[11]]. Conversely, the removal of the stressor causes A-bodies to disassemble [[11]]. Similarly, many peptide hormones are stored as amyloid fibrils in the acidic lumen of the secretory granules in endocrine cells [[16]]. The high density of the amyloid fibrils is thought to give the granules their characteristic dense core. However, upon granule secretion, the fibrils will dissociate into the monomeric form of the peptide hormone due to exposure to the higher extracellular pH [[16]].

Antimicrobial peptides (AMPs) play a central role in innate immune responses to infection [[53]]. They share a number of characteristics with the peptides and proteins that form amyloids, with both AMPs and amyloidogenic sequences being able to form pores that permeabilise membranes [[53],[54]]. Moreover, the AMPs LL-37 and protegrin-1 can assemble into amyloid-like fibrils, suggesting that they, and potentially other human AMPs, can also be classified as functional amyloids [[15],[19]].

Functional amyloid fibrils have also been proposed to participate in sexual reproduction [[55]]. Amyloid fibrils are present in the sperm acrosome, an acidic organelle in the sperm head [[12]]. These fibrils are thought to facilitate the controlled release of proteins during the acrosome reaction, a key event in the fertilisation of oocytes in which the contents of the acrosome are released [[12],[55],[56]]. Amyloids formed by the cystatin-related epididymal spermatogenicis (CRES) subgroup proteins CRES, CRES2, CRES3, and cystatin E2 are present in the epididymis [[13],[14]]. Although the role of amyloids formed by the CRES proteins is not well understood, CRES has antimicrobial activity, is important for the acrosome reaction, and is required for normal lysosomal function in the epididymis [[13],[57],[58],[59]]. Seminal fluid also contains amyloids and amyloid-like fibrils, formed respectively by peptide fragments of enzyme prostatic acid phosphatase (PAP) and semenogelin proteins (SEM1 and SEM2) [[18],[21]]. Originally identified as enhancers of viral infection [[18],[21]], these fibrils bind to and immobilise damaged sperm cells enabling their clearance by immune cells [[60]].

Artificial nanomaterials that use amyloid fibrils as a scaffold for the growth of cells can be used as functional amyloids. For example the peptide TTR1-RGD combines residues 105–115 of the human amyloidogenic protein transthyretin and the three amino acid cell adhesion motif RGD from fibronectin [[61]]. This peptide forms amyloid fibrils that can support the adhesion and growth of fibroblasts [[61]]. In another study, hen-egg white lysozyme amyloid fibrils were used as a substitute for collagen in a bone biomimetic composite, which was able to support the adhesion and growth of pre-osteoblast cells [[62]].

5. Does Functional Amyloid Fibril Assembly Generate Toxic Species?

Given the potential for the production of toxic species in amyloid assembly reactions, it is remarkable that under normal circumstances cells can produce functional amyloids fibrils without any obvious deleterious consequences. Is this because functional amyloids are intrinsically non-toxic to human cells? A number of studies indicate that this is not the case; thus, the distinction between functional amyloids and pathological amyloids is not always clear-cut.

Amyloid fibrils formed from the peptide hormones glucagon, α-helical corticotropin-releasing factor, glucagon-like peptide 2, and urocortin 3 reduce cell viability when incubated with cultured cells and primary neurons [[16]]. Likewise, amyloid fibrils formed by the seminal PAP peptide fragment are toxic to a neuronal cell line [[63]]. Perturbation of PMEL fibril assembly may also result in the production of toxic amyloids. PMEL is synthesised as a transmembrane glycoprotein precursor; subsequent proteolytic processing releases the N-terminal Mα fragment that forms the fibril core [[17],[50],[51],[64],[65],[66],[67],[68]]. The chicken PMEL Dominant White (DW) mutation results in the formation of abnormal compact fibrillar structures in cells, the loss of melanosomes and reduced cell viability [[50],[51],[69],[70]]. Crucially, this is a more severe phenotype that of the mouse PMEL knockout, which only results in a modest loss of pigmentation [[71]]. The DW mutant has a three-amino acid insertion in the transmembrane domain, a region of the protein that does not form part of the Mα fibril core [[70]]. This mutation has no effect on either the trafficking of PMEL to melanosomes or on its proteolytic processing, but instead causes abnormal oligomerisation of the transmembrane domain and/or association with membranes [[69]]. This may alter the assembly of PMEL resulting in the formation of increased numbers of toxic oligomers or the formation of abnormal fibril polymorphs that are toxic to the cells [[69]].

Surprisingly, the archetype disease-associated amyloid Aβ may itself be a functional amyloid that acts as an AMP [[72],[73],[74]]. Aβ exhibits antimicrobial properties that target pathogenic bacteria and fungi in vitro and in Caenorhabditis elegans and mouse models [[72],[73]]. The aggregation of Aβ into amyloids is central to its proposed antimicrobial properties, with assembly intermediates and amyloid fibrils interacting with microbial cell walls to inhibit microbial adhesion to host cells and to agglutinate the microorganisms [[72],[73],[74]]. Consistent with an antimicrobial role for Aβ, there are clear parallels with AMPs such as LL-37. Indeed, LL-37 not only exhibits antimicrobial properties and forms amyloid-like fibrils, but can also be toxic to host cells [[73],[75],[76],[77],[78],[79]].

The potential for the toxicity of amyloids is also relevant for the biocompatibility of nanomaterials that incorporate amyloid fibrils. Whilst TTR1-RGD amyloid fibrils can support cell growth initially, a reduction in cell viability is observed in longer-term cultures using these fibrils as a scaffold for cells [[61],[80]]. Though in this instance toxicity could be associated with the use of the TTR1 sequence from transythretin, a protein which forms amyloids in transythretin amyloidosis [[4],[5],[6],[7]].

It is also worth noting that the induction of cell death can be a normal physiological function of amyloids, with RIP1- and RIP3-forming amyloid fibrils in cells undergoing regulated necrosis [[20]]. Cell death is thought to be induced via the activation of RIP3 kinase substrates and not via the formation of toxic amyloid species [[20]], although any coincidental toxicity associated with RIP1/RIP3 fibril formation could amplify the necrotic effects of the signaling pathway. RIP1/RIP3 mediated necrosis is also activated in pathological processes such as ischemic injury and damaging inflammatory processes [[81]]. Thus, even though their normal function is performed, RIP1/RIP3 fibrils can be involved in disease.

6. How Do Cells Avert Toxicity in Functional Amyloid Assembly?

The potential for toxicity exhibited by amyloid fibrils and their assembly intermediates highlights that functional amyloid assembly must be tightly controlled. A full picture for how cells prevent functional amyloid toxicity is lacking, but a number of protective mechanisms could come into play (Figure 2).

6.1. Regulating the Level of the Amyloidogenic Peptides and Proteins

Elevated levels of amyloidogenic peptides and proteins either through increased expression, decreased degradation or a combination thereof, are thought to be a key factor in the development of amyloidoses [[82],[83]]. For example, Alzheimer’s disease and DRA are associated with elevated levels of monomeric Aβ peptides and β2m respectively, which can result in their aggregation [[84],[85]]. Thus, the level of the precursors of functional fibrils amyloids will require tight regulation, as too much of the amyloidogenic precursor could lead to unwanted amyloid formation. Indeed, given the antimicrobial activity of Aβ [[72],[73],[74]] and the role attributed to inflammation in Alzheimer’s disease [[86]], it is tempting to speculate that amyloid formation and cellular toxicity in Alzheimer’s disease could also result from overproduction of Aβ peptides in dysregulated immune responses to either infection or sterile inflammation.

Proteolytic processing may represent one mechanism cells use to regulate the level of amyloidogenic peptides and proteins. Analogous to Aβ peptides, which are generated by cleavage of the amyloid precursor protein by β-secretases and γ-secretases, PMEL is processed by proteases prior to assembling into amyloids [[51],[64],[65],[66],[67],[68],[87]]. The endoplasmic reticulum is the site of synthesis of PMEL and the protein traffics to by melanosomes via the Golgi apparatus and early endosomes [[51]]. PMEL is subjected to proteolytic cleavage in the trans-Golgi network and endosomes to liberate the fibril forming Mα fragment [[64],[65],[66],[67],[68]]. Thus, proteolytic processing may not only regulate the level of the Mα fragment, but it will also ensure that PMEL amyloid fibrils do not assemble prematurely in the secretory pathway. Proteolytic processing may also regulate the production of seminal amyloid and amyloid-like fibrils, which are formed by peptide fragments of PAP and semenogelin proteins [[18],[21]].

6.2. Minimising the Production of Prefibrillar Oligomers

Little is known about the oligomers produced in the assembly of functional amyloids. Nonetheless, these assembly reactions must pose a particular risk for cells due to the inherent potential for the production of toxic oligomers when amyloids are assembled [[30],[31],[32]]. Indeed, both acrosomes and the epididymis contain material recognised by the antibody A11, which binds to toxic prefibrillar oligomers generated from an array of different amyloidogenic precursors [[12],[13],[25]]. Thus, it may not be possible to prevent the formation of toxic prefibrillar oligomers in functional amyloid assembly. Functional amyloid assembly may instead minimise the formation of toxic prefibrillar oligomers to below a threshold that causes deleterious effects. PMEL may achieve this by assembling into fibrils at a rate that is orders of magnitude faster than that observed for the disease-associated sequences Aβ1-40 and α-synuclein [[17]]. This rapid assembly of fibrils should minimise the level of prefibrillar PMEL oligomers, limiting their ability to cause toxicity. It is unknown, however, whether rapid assembly is a feature of other functional amyloid fibrils. Furthermore, it is important to note that prefibrillar oligomers are only one potential source of toxicity, with mature amyloid fibrils and fibril-derived oligomers also exhibiting deleterious effects [[43],[44],[45],[47],[48],[49]].

6.3. Controlling Assembly of Functional Amyloid Fibrils with other Molecules

An additional level of regulation to the assembly of a number of functional amyloid fibrils may be provided by molecules that promote fibril assembly, ensuring fibrils only form when and where required. Proteins stored in A-bodies have an amyloid-converting motif (ACM), which corresponds to an arginine/histidine rich region flanking an amyloidogenic stretch of residues [[11]]. Yet these proteins do not form amyloids spontaneously in cells. Instead expression of rIGSRNA induced by stressors is required to seed assembly of proteins with ACMs into fibrils, potentially via interaction between the RNA and the arginine/histidine rich region flanking the amyloidogenic stretch [[11]]. Similarly, many of the peptide hormones stored within endocrine granules as amyloid fibrils do not form fibrils spontaneously in vitro at the acidic pH of the granule lumen [[16]]. Amyloid formation by many of these peptides is stimulated by glycosaminoglycans (GAGs), which are also present within endocrine granules [[16],[88]]. In addition to their role in promoting functional amyloid assembly these molecules may help to prevent toxicity. Indeed, it has been shown that GAGs by accelerating fibril formation can reduce toxicity associated with amyloid assembly reactions, presumably by lowering the level and lifespan of prefibrillar oligomers [[89],[90],[91]]. Moreover, GAGs can prevent the disruption of lipid membranes by preformed amyloid fibrils [[92]].

6.4. Sequestering Functional Amyloid Assembly Reactions within Membrane Bound Compartments

PMEL assembles into fibrils within early endosomes and melanosomes, whereas amyloid fibrils formed by peptide hormones and acrosomal matrix proteins assemble within the lumen of endocrine granules and acrosomes, respectively [[12],[16],[17]]. These membrane bound organelles provide an acidic environment that is optimal for the assembly of the amyloid fibrils [[12],[16],[17],[50],[51]]. The surrounding membrane may also act as a physical barrier to prevent unwanted interactions between amyloids and other cellular components. Yet, the sequestration of amyloids within membrane bound organelles may itself present a problem. Membranes are a key cellular target in amyloidoses, with prefibrillar oligomers, amyloid fibrils, and fibril-derived oligomers being shown to permeabilise lipid membranes [[33],[34],[43],[44],[45]]. The extent of membrane disruption is, however, dependent on the lipid composition of the membranes [[93],[94]]. This may be reflected in the lipid profiles of organelles in which functional amyloids are assembled.

6.5. Disassembly of Functional Amyloid Fibrils

Amyloidoses are characterised by the progressive accumulation of amyloid deposits, suggesting that these diseases are caused, at least in part, by a failure to remove these unwanted protein aggregates [[82],[83]]. In contrast, a number of functional amyloids have been shown to disassemble readily under physiological conditions. A-body formation in the nucleus is reversible, the removal of the stressors resulting in their chaperone-dependent disassembly [[11]]. PMEL amyloid fibrils, as well as those formed by peptide hormones and acrosomal proteins are localised to acidic organelles and disassemble when exposed to neutral pH [[12],[16],[95],[96]]. Moreover, no stable oligomers are observed when fibrils of the PMEL repeat domain, which is part of the Mα fragment, disassemble at neutral pH [[96]]. The ability to disassemble rapidly into monomers is clearly important for the function of peptide hormones and may facilitate the dispersal of acrosomal matrix proteins during the acrosome reaction. It will also ensure that fibrils released by cells disassemble into monomers before either the fibrils or fibril-derived oligomers have the opportunity to cause any deleterious effects. Similarly, if the membranes surrounding the organelles in which amyloid fibrils are localised become damaged, any fibrils that inadvertently access the cytosol would presumably also rapidly disassemble.

7. Summary and Remaining Questions

In summary, functional amyloid fibrils participate in an array of physiological processes, but their assembly could pose significant risks for cells. A number of mechanisms that may help avert the toxicity of functional amyloids and their assembly intermediates can be proposed. These include regulating the levels of amyloidogenic peptides and proteins, minimising the formation of prefibrillar oligomers, sequestering fibril assembly inside membrane bound compartments, regulating assembly with GAGs and RNAs and being able to disassemble amyloid fibrils. However, questions still remain about why functional amyloids have no pronounced ill effect on the cells responsible for their production.

Does the dysregulation of functional amyloid production result in disease? Of particular interest is whether Alzheimer’s disease is caused by the overproduction of a functional amyloid.

Do functional amyloid assembly reactions produce toxic oligomers? Studies suggest that toxic prefibrillar oligomers are a common feature of amyloid assembly, yet surprisingly little is known about the properties of oligomers associated with functional amyloids.

Are functional amyloids able to assemble more rapidly than disease-associated amyloids, thus limiting the production of any toxic prefibrillar oligomers?

In addition to promoting the assembly of functional amyloids do rIGSRNA and GAGs also prevent amyloid toxicity?

How can functional amyloid fibrils be assembled and stored within membrane bound compartments when cellular membranes represent a key target in amyloid toxicity?

Crucially, a better understanding of how cells prevent toxicity in the production of functional amyloids will provide insights into how to prevent tissue degeneration in amyloidoses.

Acknowledgements

Acknowledgments

This work was supported by the Wellcome Trust Grant 092896 and the ERC Grant Agreement 32240 to E.W.H. and M.P.J.

References

  1. J.D. SipeA.S. CohenReview: History of the amyloid fibrilJ. Struct. Biol.2000130889810.1006/jsbi.2000.422110940217
  2. R. KisilevskyS. RaimondiV. BellottiHistorical and current concepts of fibrillogenesis and in vivo amyloidogenesis: Implications of amyloid tissue targetingFront. Mol. Biosci.201631710.3389/fmolb.2016.0001727243018
  3. J.N. BuxbaumR.P. LinkeA molecular history of the amyloidosesJ. Mol. Biol.201242114215910.1016/j.jmb.2012.01.02422321796
  4. P. WestermarkM.D. BensonJ.N. BuxbaumA.S. CohenB. FrangioneS.I. IkedaC.L. MastersG. MerliniM.J. SaraivaJ.D. SipeAmyloid: Toward terminology clarification—Report from the nomenclature committee of the international society of amyloidosisAmyloid2005121410.1080/1350612050003219616076605
  5. J.D. SipeM.D. BensonJ.N. BuxbaumS.I. IkedaG. MerliniM.J. SaraivaP. WestermarkAmyloid fibril proteins and amyloidosis: Chemical identification and clinical classification international society of amyloidosis 2016 nomenclature guidelinesAmyloid20162320921310.1080/13506129.2016.125798627884064
  6. T.P. KnowlesM. VendruscoloC.M. DobsonThe amyloid state and its association with protein misfolding diseasesNat. Rev. Mol. Cell Biol.20141538439610.1038/nrm381024854788
  7. F. ChitiC.M. DobsonProtein misfolding, amyloid formation, and human disease: A summary of progress over the last decadeAnnu. Rev. Biochem.201786276810.1146/annurev-biochem-061516-04511528498720
  8. F. ChitiC.M. DobsonProtein misfolding, functional amyloid, and human diseaseAnnu. Rev. Biochem.20067533336610.1146/annurev.biochem.75.101304.12390116756495
  9. C.L.L. PhamA.H. KwanM. SundeFunctional amyloid: Widespread in nature, diverse in purposeEssays Biochem.20145620721910.1042/bse056020725131597
  10. D. OtzenFunctional amyloid turning swords into plowsharesPrion2010425626410.4161/pri.4.4.1367620935497
  11. T.E. AudasD.E. AudasM.D. JacobJ.J. HoM. KhachoM. WangJ.K. PereraC. GardinerC.A. BennettT. HeadAdaptation to stressors by systemic protein amyloidogenesisDev. Cell20163915516810.1016/j.devcel.2016.09.00227720612
  12. B. GuyonnetN. EggeG.A. CornwallFunctional amyloids in the mouse sperm acrosomeMol. Cell Biol.2014342624263410.1128/MCB.00073-1424797071
  13. S. WhellyS. JohnsonJ. PowellC. BorchardtM.C. HastertG.A. CornwallNonpathological extracellular amyloid is present during normal epididymal sperm maturationPLoS ONE20127e3639410.1371/journal.pone.003639422570708
  14. S. WhellyA. MuthusubramanianJ. PowellS. JohnsonM.C. HastertG.A. CornwallCystatin-related epididymal spermatogenic subgroup members are part of an amyloid matrix and associated with extracellular vesicles in the mouse epididymal lumenMol. Hum. Reprod.20162272974410.1093/molehr/gaw04927445316
  15. R. SoodY. DomanovM. PietiainenV.P. KontinenP.K.J. KinnunenBinding of LL-37 to model biomembranes: Insight into target vs. host cell recognitionBiochem. Biophys. Acta2008177898399610.1016/j.bbamem.2007.11.01618166145
  16. S.K. MajiM.H. PerrinM.R. SawayaS. JessbergerK. VadodariaR.A. RissmanP.S. SingruK.P. NilssonR. SimonD. SchubertFunctional amyloids as natural storage of peptide hormones in pituitary secretory granulesScience200932532833210.1126/science.117315519541956
  17. D.M. FowlerA.V. KoulovC. Alory-JostM.S. MarksW.E. BalchJ.W. KellyFunctional amyloid formation within mammalian tissuePLoS Biol.2006410010710.1371/journal.pbio.004000616300414
  18. J. MunchE. RuckerL. StandkerK. AdermannC. GoffinetM. SchindlerS. WildumR. ChinnaduraiD. RajanA. SpechtSemen-derived amyloid fibrils drastically enhance HIV infectionCell20071311059107110.1016/j.cell.2007.10.01418083097
  19. H. JangF.T. ArceM. MustataS. RamachandranR. CaponeR. NussinovR. LalAntimicrobial protegrin-1 forms amyloid-like fibrils with rapid kinetics suggesting a functional linkBiophys. J.20111001775178310.1016/j.bpj.2011.01.07221463591
  20. J. LiT. McQuadeA.B. SiemerJ. NapetschnigK. MoriwakiY.S. HsiaoE. DamkoD. MoquinT. WalzA. McDermottThe RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosisCell201215033935010.1016/j.cell.2012.06.01922817896
  21. N.R. RoanJ.A. MullerH.C. LiuS. ChuF. ArnoldC.M. SturzelP. WaltherM. DongH.E. WitkowskaF. KirchhoffPeptides released by physiological cleavage of semen coagulum proteins form amyloids that enhance HIV infectionCell Host Microbe20111054155010.1016/j.chom.2011.10.01022177559
  22. R. TyckoR.B. WicknerMolecular structures of amyloid and prion fibrils: Consensus versus controversyAccounts Chem. Res.2013461487149610.1021/ar300282r23294335
  23. R. KayedE. HeadF. SarsozaT. SaingC.W. CotmanM. NeculaL. MargolJ. WuL. BreydoJ.L. ThompsonFibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomersMol. Neurodegener.200721810.1186/1750-1326-2-1817897471
  24. B. O’NuallainR. WetzelConformational Abs recognizing a generic amyloid fibril epitopeProc. Natl. Acad. Sci. USA2002991485149010.1073/pnas.02266259911818542
  25. R. KayedE. HeadJ.L. ThompsonT.M. McIntireS.C. MiltonC.W. CotmanC.G. GlabeCommon structure of soluble amyloid oligomers implies common mechanism of pathogenesisScience200330048648910.1126/science.107946912702875
  26. A.T. PetkovaR.D. LeapmanZ. GuoW.M. YauM.P. MattsonR. TyckoSelf-propagating, molecular-level polymorphism in Alzheimer’s β-amyloid fibrilsScience200530726226510.1126/science.110585015653506
  27. W. QiangW.M. YauJ.X. LuJ. CollingeR. TyckoStructural variation in amyloid-β fibrils from alzheimer's disease clinical subtypesNature201754121722110.1038/nature2081428052060
  28. M. StefaniBiochemical and biophysical features of both oligomer/fibril and cell membrane in amyloid cytotoxicityFEBS J.20102774602461310.1111/j.1742-4658.2010.07889.x20977664
  29. U. SenguptaA.N. NilsonR. KayedThe role of amyloid-β oligomers in toxicity, propagation, and immunotherapyEbiomedicine20166424910.1016/j.ebiom.2016.03.03527211547
  30. M. BucciantiniE. GiannoniF. ChitiF. BaroniL. FormigliJ. ZurdoN. TaddeiG. RamponiC.M. DobsonM. StefaniInherent toxicity of aggregates implies a common mechanism for protein misfolding diseasesNature200241650751110.1038/416507a11932737
  31. M. BucciantiniG. CalloniF. ChitiL. FormigliD. NosiC.M. DobsonM. StefaniPrefibrillar amyloid protein aggregates share common features of cytotoxicityJ. Biol. Chem.2004279313743138210.1074/jbc.M40034820015133040
  32. S. BaglioniF. CasamentiM. BucciantiniL.M. LuheshiN. TaddeiF. ChitiC.M. DobsonM. StefaniPrefibrillar amyloid aggregates could be generic toxins in higher organismsJ. Neurosci.2006268160816710.1523/JNEUROSCI.4809-05.200616885229
  33. A. DemuroE. MinaR. KayedS.C. MiltonI. ParkerC.G. GlabeCalcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomersJ. Biol. Chem.2005280172941730010.1074/jbc.M50099720015722360
  34. R. KayedY. SokolovB. EdmondsT.M. McIntireS.C. MiltonJ.E. HallC.G. GlabePermeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseasesJ. Biol. Chem.2004279463634636610.1074/jbc.C40026020015385542
  35. D.M. WalshB.P. TsengR.E. RydelM.B. PodlisnyD.J. SelkoeThe oligomerization of amyloid β-protein begins intracellularly in cells derived from human brainBiochemistry200039108311083910.1021/bi001048s10978169
  36. Y.R. ChenC.G. GlabeDistinct early folding and aggregation properties of alzheimer amyloid-β peptides Aβ40 and Aβ42: Stable trimer or tetramer formation by Aβ42J. Biol. Chem.2006281244142442210.1074/jbc.M60236320016809342
  37. M. AhmedJ. DavisD. AucoinT. SatoS. AhujaS. AimotoJ.I. ElliottW.E. Van NostrandS.O. SmithStructural conversion of neurotoxic amyloid-β1–42 oligomers to fibrilsNat. Struct. Mol. Biol.20101756156710.1038/nsmb.179920383142
  38. R.W. HeplerK.M. GrimmD.D. NahasR. BreeseE.C. DodsonP. ActonP.M. KellerM. YeagerH. WangP. ShughrueSolution state characterization of amyloid β-derived diffusible ligandsBiochemistry200645151571516710.1021/bi061850f17176037
  39. M.P. LambertA.K. BarlowB.A. ChromyC. EdwardsR. FreedM. LiosatosT.E. MorganI. RozovskyB. TrommerK.L. ViolaDiffusible, nonfibrillar ligands derived from Aβ1–42 are potent central nervous system neurotoxinsProc. Natl. Acad. Sci. USA1998956448645310.1073/pnas.95.11.64489600986
  40. S. LesneM.T. KohL. KotilinekR. KayedC.G. GlabeA. YangM. GallagherK.H. AsheA specific amyloid-β protein assembly in the brain impairs memoryNature200644035235710.1038/nature0453316541076
  41. A.R.A. LadiwalaJ.C. LinS.S. BaleA.M. Marcelino-CruzM. BhattacharyaJ.S. DordickP.M. TessierResveratrol selectively remodels soluble oligomers and fibrils of amyloid Aβ into off-pathway conformersJ. Biol. Chem.2010285242282423710.1074/jbc.M110.13310820511235
  42. S. CampioniB. ManniniM. ZampagniA. PensalfiniC. ParriniE. EvangelistiA. ReliniM. StefaniC.M. DobsonC. CecchiA causative link between the structure of aberrant protein oligomers and their toxicityNat. Chem. Biol.2010614014710.1038/nchembio.28320081829
  43. W.F. XueA.L. HellewellW.S. GosalS.W. HomansE.W. HewittS.E. RadfordFibril fragmentation enhances amyloid cytotoxicityJ. Biol. Chem.2009284342723428210.1074/jbc.M109.04980919808677
  44. L. MilanesiT. SheynisW.F. XueE.V. OrlovaA.L. HellewellR. JelinekE.W. HewittS.E. RadfordH.R. SaibilDirect three-dimensional visualization of membrane disruption by amyloid fibrilsProc. Natl. Acad. Sci. USA2012109204552046010.1073/pnas.120632510923184970
  45. M.F.M. EngelL. KhemtemourianC.C. KleijerH.J.D. MeeldijkJ. JacobsA.J. VerkleijB. de KruijffJ.A. KillianJ.W.M. HoppenerMembrane damage by human islet amyloid polypeptide through fibril growth at the membraneProc. Natl. Acad. Sci. USA20081056033603810.1073/pnas.070835410518408164
  46. K.W. TippingP. van Oosten-HawleE.W. HewittS.E. RadfordAmyloid fibres: Inert end-stage aggregates or key players in disease?Trends Biochem. Sci.20154071972710.1016/j.tibs.2015.10.00226541462
  47. K.W. TippingT.K. KaramanosT. JakhriaM.G. IadanzaS.C. GoodchildR. TumaN.A. RansonE.W. HewittS.E. RadfordpH-induced molecular shedding drives the formation of amyloid fibril-derived oligomersProc. Natl. Acad. Sci. USA20151125691569610.1073/pnas.142317411225902516
  48. N. CremadesS.I. CohenE. DeasA.Y. AbramovA.Y. ChenA. OrteM. SandalR.W. ClarkeP. DunneF.A. AprileDirect observation of the interconversion of normal and toxic forms of α-synucleinCell20121491048105910.1016/j.cell.2012.03.03722632969
  49. S.I.A. CohenS. LinseL.M. LuheshiE. HellstrandD.A. WhiteL. RajahD.E. OtzenM. VendruscoloC.M. DobsonT.P.J. KnowlesProliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanismProc. Natl. Acad. Sci. USA20131109758976310.1073/pnas.121840211023703910
  50. B. WattG. van NielG. RaposoM.S. MarksPMEL: A pigment cell-specific model for functional amyloid formationPigment Cell Melanoma Res.20132630031510.1111/pcmr.1206723350640
  51. C. BissigL. RochinG. van NielPMEL amyloid fibril formation: The bright steps of pigmentationInt. J. Mol. Sci.201617143810.3390/ijms1709143827589732
  52. T. Vanden BergheB. HassanniaP. VandenabeeleAn outline of necrosome triggersCell Mol. Life Sci.2016732137215210.1007/s00018-016-2189-y27052312
  53. B.L. KaganH. JangR. CaponeF. Teran ArceS. RamachandranR. LalR. NussinovAntimicrobial properties of amyloid peptidesMol. Pharm.2012970871710.1021/mp200419b22081976
  54. N.B. LastA.D. MirankerCommon mechanism unites membrane poration by amyloid and antimicrobial peptidesProc. Natl. Acad. Sci. USA20131106382638710.1073/pnas.121905911023576726
  55. A. HewetsonH.Q. DoC. MyersA. MuthusubramanianR.B. SuttonB.J. WylieG.A. CornwallFunctional amyloids in reproductionBiomolecules201774610.3390/biom703004628661450
  56. G. BerrutiC. PaiardiAcrosome biogenesis: Revisiting old questions to yield new insightsSpermatogenesis20111959810.4161/spmg.1.2.1682022319656
  57. L. WangQ. YuanS.H. ChenH. CaiM.G. LuY. LiuC. XuAntimicrobial activity and molecular mechanism of the CRES proteinPLoS ONE20127e4836810.1371/journal.pone.004836823185254
  58. K.M. ChauG.A. CornwallReduced fertility in vitro in mice lacking the cystatin cres (cystatin-related epididymal spermatogenic): Rescue by exposure of spermatozoa to dibutyryl camp and isobutylmethylxanthineBiol. Reprod.20118414015210.1095/biolreprod.110.08485520811015
  59. A.D. ParentG.A. CornwallL.Y. LiuC.E. SmithL. HermoAlterations in the testis and epididymis associated with loss of function of the cystatin-related epididymal spermatogenic (CRES) proteinJ. Androl.20113244446310.2164/jandrol.110.01069421051588
  60. N.R. RoanN. Sandi-MonroyN. KohgadaiS.M. UsmaniK.G. HamilJ. NeidlemanM. MontanoL. StandkerA. RockerM. CavroisSemen amyloids participate in spermatozoa selection and clearanceElife20176e2488810.7554/eLife.2488828653619
  61. S.L. GrasA.K. TicklerA.M. SquiresG.L. DevlinM.A. HortonC.M. DobsonC.E. MacPheeFunctionalised amyloid fibrils for roles in cell adhesionBiomaterials2008291553156210.1016/j.biomaterials.2007.11.02818164758
  62. C. LiA.K. BornT. SchweizerM. Zenobi-WongM. CerrutiR. MezzengaAmyloid-hydroxyapatite bone biomimetic compositesAdv. Mater.2014263207321210.1002/adma.20130619824634054
  63. A.K. EliasD. ScanlonI.F. MusgraveJ.A. CarverSEVI, the semen enhancer of HIV infection along with fragments from its central region, form amyloid fibrils that are toxic to neuronal cellsBiochim. Biophys. Acta201418441591159810.1016/j.bbapap.2014.06.00624948476
  64. J.F. BersonA.C. TheosD.C. HarperD. TenzaG. RaposoM.S. MarksProprotein convertase cleavage liberates a fibrillogenic fragment of a resident glycoprotein to initiate melanosome biogenesisJ. Cell Biol.200316152153310.1083/jcb.20030207212732614
  65. R.M. LeonhardtN. VigneronC. RahnerP. CresswellProprotein convertases process PMEL17 during secretionJ. Biol. Chem.20112869321933710.1074/jbc.M110.16808821247888
  66. L. RochinI. HurbainL. SerneelsC. FortB. WattP. LeblancM.S. MarksB. De StrooperG. RaposoG. van NielBACE2 processes PMEL to form the melanosome amyloid matrix in pigment cellsProc. Natl. Acad. Sci. USA2013110106581066310.1073/pnas.122074811023754390
  67. M. KawaguchiY. HozumiT. SuzukiADAM protease inhibitors reduce melanogenesis by regulating PMEL17 processing in human melanocytesJ. Dermatol. Sci.20157813314210.1016/j.jdermsci.2015.02.02025818872
  68. M.P. KummerH. MaruyamaC. HuelsmannS. BachesS. WeggenE.H. KooFormation of PMEL17 amyloid is regulated by juxtamembrane metalloproteinase cleavage, and the resulting C-terminal fragment is a substrate for gamma-secretaseJ. Biol. Chem.20092842296230610.1074/jbc.M80890420019047044
  69. B. WattD. TenzaM.A. LemmonS. KerjeG. RaposoL. AnderssonM.S. MarksMutations in or near the transmembrane domain alter PMEL amyloid formation from functional to pathogenicPLoS Genet.20117e100228610.1371/journal.pgen.100228621949659
  70. S. KerjeP. SharmaU. GunnarssonH. KimS. BagchiR. FredrikssonK. SchutzP. JensenG. von HeijneR. OkimotoThe Dominant white, Dun and Smoky Color variants in chicken are associated with insertion/deletion polymorphisms in the PMEL17 geneGenetics20041681507151810.1534/genetics.104.02799515579702
  71. A.R. HellstromB. WattS.S. FardD. TenzaP. MannstromK. NarfstromB. EkestenS. ItoK. WakamatsuJ. LarssonInactivation of PMEL alters melanosome shape but has only a subtle effect on visible pigmentationPLoS Genet.20117e100228510.1371/journal.pgen.100228521949658
  72. S.J. SosciaJ.E. KirbyK.J. WashicoskyS.M. TuckerM. IngelssonB. HymanM.A. BurtonL.E. GoldsteinS. DuongR.E. TanziThe Alzheimer's disease-associated amyloid β-protein is an antimicrobial peptidePLoS ONE20105e950510.1371/journal.pone.000950520209079
  73. D.K. KumarS.H. ChoiK.J. WashicoskyW.A. EimerS. TuckerJ. GhofraniA. LefkowitzG. McCollL.E. GoldsteinR.E. TanziAmyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer's diseaseSci. Transl. Med.20168340ra37210.1126/scitranslmed.aaf105927225182
  74. P. SpitzerM. CondicM. HerrmannT.J. ObersteinM. Scharin-MehlmannD.F. GilbertO. FriedrichT. GromerJ. KornhuberR. LangAmyloidogenic amyloid-β-peptide variants induce microbial agglutination and exert antimicrobial activitySci. Rep.201663222810.1038/srep3222827624303
  75. J. SallM. CarlssonO. GidlofA. HolmJ. HumlenJ. OhmanD. SvenssonB.O. NilssonD. JonssonThe antimicrobial peptide LL-37 alters human osteoblast Ca2+ handling and induces Ca2+-independent apoptosisJ. Innate Immun.2013529030010.1159/00034658723406612
  76. P.G. BarlowP.E. BeaumontC. CosseauA. MackellarT.S. WilkinsonR.E. HancockC. HaslettJ.R. GovanA.J. SimpsonD.J. DavidsonThe human cathelicidin LL-37 preferentially promotes apoptosis of infected airway epitheliumAm. J. Respir. Cell Mol. Biol.20104369270210.1165/rcmb.2009-0250OC20097832
  77. H.N. LiP.G. BarlowJ. BylundA. MackellarA. BjorstadJ. ConlonP.S. HiemstraC. HaslettM. GrayA.J. SimpsonSecondary necrosis of apoptotic neutrophils induced by the human cathelicidin LL-37 is not proinflammatory to phagocytosing macrophagesJ. Leukoc. Biol.20098689190210.1189/jlb.020905019581375
  78. Z.F. ZhangG. CherryholmesJ.E. ShivelyNeutrophil secondary necrosis is induced by LL-37 derived from cathelicidinJ. Leukoc. Biol.20088478078810.1189/jlb.020808618524973
  79. C.D. CiorneiH. TapperA. BjartellN.H. SternbyM. BodelssonHuman antimicrobial peptide LL-37 is present in atherosclerotic plaques and induces death of vascular smooth muscle cells: A laboratory studyBMC Cardiovasc. Disord.200664910.1186/1471-2261-6-4917181861
  80. M.N. BongiovanniS.L. GrasBioactive TTR105–115-based amyloid fibrils reduce the viability of mammalian cellsBiomaterials20154610511610.1016/j.biomaterials.2014.12.03925678120
  81. K.W. WegnerD. SalehA. DegterevComplex pathologic roles of RIPK1 and RIPK3: Moving beyond necroptosisTrends Pharmacol. Sci.20173820222510.1016/j.tips.2016.12.00528126382
  82. M.S. HippS.H. ParkF.U. HartlProteostasis impairment in protein-misfolding and -aggregation diseasesTrend Cell Biol.20142450651410.1016/j.tcb.2014.05.00324946960
  83. M.P. JacksonE.W. HewittCellular proteostasis: Degradation of misfolded proteins by lysosomesEssays Biochem.20166017318010.1042/EBC2016000527744333
  84. R.J. O’BrienP.C. WongAmyloid precursor protein processing and alzheimer’s diseaseAnnu. Rev. Neurosci.20113418520410.1146/annurev-neuro-061010-11361321456963
  85. T.B. DruekeZ.A. Massyβ2-microglobulinSemin. Dial.20092237838010.1111/j.1525-139X.2009.00584.x19708985
  86. F.L. HeppnerR.M. RansohoffB. BecherImmune attack: The role of inflammation in Alzheimer diseaseNat. Rev. Neurosci.20151635837210.1038/nrn388025991443
  87. D.J. SelkoeJ. HardyThe amyloid hypothesis of Alzheimer’s disease at 25 yearsEMBO Mol. Med.2016859560810.15252/emmm.20160621027025652
  88. A. ZaniniG. GiannattasioG. NussdorferR.K. MargolisR.U. MargolisJ. MeldolesiMolecular-organization of prolactin granules. II. Characterization of glycosaminoglycans and glycoproteins of the bovine prolactin matrixJ. Cell Biol.19808626027210.1083/jcb.86.1.2607419576
  89. J. Di DomizioR. ZhangL.J. StaggM. GageaM. ZhuoJ.E. LadburyW. CaoBinding with nucleic acids or glycosaminoglycans converts soluble protein oligomers to amyloidJ. Biol. Chem.201228773674710.1074/jbc.M111.23847722102410
  90. J. MadineD.A. MiddletonComparison of aggregation enhancement and inhibition as strategies for reducing the cytotoxicity of the aortic amyloid polypeptide medinEur. Biophys. J. Biophys.2010391281128810.1007/s00249-010-0581-320162269
  91. S. VilasiR. SarcinaR. MaritatoA. De SimoneG. IraceI. SirangeloHeparin induces harmless fibril formation in amyloidogenic W7FW14F apomyoglobin and amyloid aggregation in wild-type protein in vitroPLoS ONE20116e2207610.1371/journal.pone.002207621779376
  92. T. SheynisA. FriedigerW.F. XueA.L. HellewellK.W. TippingE.W. HewittS.E. RadfordR. JelinekAggregation modulators interfere with membrane interactions of β2-microglobulin fibrilsBiophys. J.201310574575510.1016/j.bpj.2013.06.01523931322
  93. S.C. GoodchildT. SheynisR. ThompsonK.W. TippingW.F. XueN.A. RansonP.A. BealesE.W. HewittS.E. Radfordβ2-microglobulin amyloid fibril-induced membrane disruption is enhanced by endosomal lipids and acidic pHPLoS ONE20149e10449210.1371/journal.pone.010449225100247
  94. E. EvangelistiC. CecchiR. CascellaC. SgromoM. BecattiC.M. DobsonF. ChitiM. StefaniMembrane lipid composition and its physicochemical properties define cell vulnerability to aberrant protein oligomersJ. Cell Sci.20121252416242710.1242/jcs.09843422344258
  95. R.P. McGlincheyF. ShewmakerP. McPhieB. MonterrosoK. ThurberR.B. WicknerThe repeat domain of the melanosome fibril protein PMEL17 forms the amyloid core promoting melanin synthesisProc. Natl. Acad. Sci. USA2009106137311373610.1073/pnas.090650910619666488
  96. R.P. McGlincheyJ.M. GruschusA. NagyJ.C. LeeProbing fibril dissolution of the repeat domain of a functional amyloid, PMEL17, on the microscopic and residue levelBiochemistry201150105671056910.1021/bi201578h22092386
The underlying source XML for this text is taken from https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5745454/fullTextXML. The license for the article is Creative Commons Attribution. The main subject has been identified as amyloidosis.